Jinhe Biotechnology CO., LTD. (002688.SZ)
- Previous Close
6.18 - Open
6.30 - Bid 6.37 x --
- Ask 6.38 x --
- Day's Range
6.19 - 6.43 - 52 Week Range
3.40 - 8.69 - Volume
97,292,860 - Avg. Volume
48,265,126 - Market Cap (intraday)
4.923B - Beta (5Y Monthly) --
- PE Ratio (TTM)
45.57 - EPS (TTM)
0.14 - Earnings Date --
- Forward Dividend & Yield 0.10 (1.62%)
- Ex-Dividend Date May 31, 2024
- 1y Target Est
--
Jinhe Biotechnology CO., LTD. produces and sells veterinary medicines in China. The company offers chlortetracycline feed grade, an antimicrobial drug for the inhibition and treatment of white dysentery, enteritis, pneumonia, typhoid, paratyphoid, cholera, etc. in poultry and livestock; and chlortetracycline hydrochloride for the inhibition and treatment of pullorum disease, typhoid, and swine enteritis, as well as bacterial diseases, including paratyphoid and cholera. It also exports its products to the United States, South-east Asia, Latin America, Europe, etc. Jinhe Biotechnology CO., LTD. was founded in 1990 and is based in Dalian, China.
www.jinhe.com.cn--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 002688.SZ
View MorePerformance Overview: 002688.SZ
Trailing total returns as of 5/7/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 002688.SZ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 002688.SZ
View MoreValuation Measures
Market Cap
4.77B
Enterprise Value
6.50B
Trailing P/E
44.85
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.93
Price/Book (mrq)
2.07
Enterprise Value/Revenue
2.62
Enterprise Value/EBITDA
64.88
Financial Highlights
Profitability and Income Statement
Profit Margin
4.29%
Return on Assets (ttm)
3.29%
Return on Equity (ttm)
3.48%
Revenue (ttm)
2.48B
Net Income Avi to Common (ttm)
106.17M
Diluted EPS (ttm)
0.14
Balance Sheet and Cash Flow
Total Cash (mrq)
617.05M
Total Debt/Equity (mrq)
91.76%
Levered Free Cash Flow (ttm)
36.86M